TrialThe New England journal of medicine2019
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2,818 papers cite itlatest 60 shown
this paperpooled ittrialcites it